Weekly Movers: Regulus, Nymox, Akers…
pharmafile | July 4, 2016 | Feature | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Shares, drug trial, markets, stocks
Shares in Regulus Therapeutics (Nasdaq: RGLS) dropped after the company said it has received verbal notification from the US Food and Drug Administration (FDA) saying its trial drug RG-101 for chronic hepatitis C virus infection has been placed on clinical hold.
The action follows the reports of a second serious adverse event of jaundice.
Nymox Pharmaceutical (Nasdaq: NYMX) stock climbed nearly 14%.
The company recently reported long-term prostate cancer results in 7 year prospective study of 995 middle-aged and elderly men without cancer in the US. The trial showed the men who received fexapotide had a major reduction in incidence of prostate cancer.
In addition, the men who received fexapotide showed major reduction in incidence of prostate cancer.
Akers Biosciences (Nasdaq: AKR) shares jumped after the company said it has signed a distribution agreement for BreathScan OxiChek with Aero-Med.
Shares in Esperion Therapeutics (Nasdaq: ESPR) dropped after the company said it failed to reach an agreement with the FDA on a regulatory pathway for an LDL-C lowering indication in the US on ETC-1002 in statin intolerant patients.
Xencor (Nasdaq: XNCR) stock jumped 32% after the company said it has signed a collaboration and license agreement with Novartis (VTX: NOVN) for the development of bispecific antibodies for treating cancer.
Under the terms of the agreement, Xencor the two companies will equally share the cost to jointly develop two Xencor antibodies targeting the CD3 domain.
Shares in Tesaro (Nasdaq: TSDR) more than doubled after the company announced its Phase III trial of niraparib successfully achieved its primary endpoint of progression-free survival in ovarian cancer.
The company said a Phase III study of niraparib showed the trial drug significantly prolonged PFS compared to control among patients who are germline BRCA mutation carriers.
Tesaro said it is planning US and EU marketing submissions for the oral PARP inhibitor.
Clovis Oncology (Nasdaq: CLVS) rose after Tesaro reported positive results from late-stage trials of its ovarian cancer drug. The company is developing developing rucaparib, currently in Phase II trials for ovarian cancer that has the same target as Tesaro’s niraparib.
Anjali Shukla
Related Content
Profits over patients: US pharma spending billions on investor payouts
In 2017 Donald Trump signed the Tax Cuts and Jobs Act (TCJA), creating billions of …
Acasti’s shares plunge as new drug does not meet primary endpoint
Acasti Pharma’s shares plunged by as much as 67% this week as its drug CaPre …
Novartis exec sold off shares before Zolgensma data scandal was revealed
An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm …
